Shingo Nakamura founded Veritas In Silico and became Representative Director in 2016. He has a wide variety of hands-on experience in drug discovery research, interactions with regulatory authorities, business development, sales operations, and investment in biotech firms.

Prior to founding Veritas In Silico, Shingo served as Investing Director at INCJ, Ltd. in 2015-2017, Business Development Director at Catalent Pharma Solutions in 2011-2015, and Sales Department Manager at the Dow Chemical Company in 2011. Previously, he worked for Takeda Pharmaceutical Company Limited since 2003, where he ran an mRNA-targeted drug discovery project from 2004. He left the company in 2011 when the project was discontinued due to the company policy.

Shingo earned his Ph.D. degree (D.Eng.) in organic chemistry from the Graduate School of Engineering, Nagoya University, and passed Japan’s Class I Information Technology Engineer Examination in 2000. Then he joined the Breaker Laboratory, Yale University as a postdoctoral fellow, and conducted research on the molecular and cellular biology of nucleic acids.

Takashi Kamimura joined Veritas In Silico as a founding member and became Director in 2017. He has extensive experience such as the R&D of pharmaceuticals, business development, and the management of intellectual property, in addition to his broad network of contacts in the pharmaceutical industry and in the field of nucleic acid chemistry. He is a member of the Council of Nucleic Acids Therapeutics Society of Japan.

Prior to joining Veritas In Silico, Takashi worked for Teijin Limited and its Group Company, Teijin Pharma Limited, for more than 30 years. In his career at Teijin Group, he, having gained research experience at Scripps Research Institute for 2 years, was appointed as Head of Pharmaceutical Development Laboratories at Teijin in 2002, then moved to Teijin Pharma and served as Director of the Pharmaceutical Development Research Laboratories, Manager of the New Pharmaceutical Promotion Section (intellectual property), Manager of the Pharmaceutical Planning Department (business development), and finally Director and Executive Officer, before returning to Teijin as Executive Officer in 2013.

Takashi earned his Ph.D. degree (D. Sci.) in nucleic acid chemistry from the Interdisciplinary Graduate School of Science and Engineering, Tokyo Institute of Technology in 1983.

Hiroyuki Matsuoka joined Veritas In Silico in 2018 and was appointed as Director in 2019. He has years of experience in auditing and consulting services for companies preparing for IPO as a certified public accountant.

Prior to joining Veritas In Silico, Hiroyuki first worked at Nippon Oil Corporation (currently ENEOS Holdings, Inc.) for 7 years, where he designed pipelines and mechanical equipment in refineries as a chief mechanical engineer. He then passed the examination of the Japanese Institute of Certified Public Accountants (JICPA) and started his career as a certified public accountant, working for Ernst & Young since 2005. During his time in E&Y until 2018, he especially focused on consulting for small-sized technology companies including Veritas In Silico.

Hiroyuki earned his master’s degree in Mechanical Engineering from the Faculty of Science and Technology, Sophia University in 1992, and his master’s degree in Arts from the Energy and Mineral Resources Department, the University of Texas at Austin in 1998.

Kinichiro Kominami, Representative Director and Chief Executive Officer of Tech & FinStrategy, Inc., was appointed as Director of Veritas In Silico in 2019. He provides consulting services to startups for preparing IPO as a director, supports major companies to branch out into new businesses, and gives support to venture capital firms and financial institutions.

Kinichiro founded Tech & FinStrategy in 2017. Prior to founding the company, he worked in the securities industry since 2001. Most recently, he conducted research on IPOs and coordinated the cooperation between industry and academia as Corporate Group Director of the Domestic Business Division, Mizuho Securities Co., Ltd. Before Mizuho Securities, he conducted research on IPOs in the Research Division of Nomura Research & Advisory Co., Ltd. (Nomura Securities Co., Ltd.) and invested in 24 biotech firms in the Investment Division, 12 of which have now been listed on the Tokyo Stock Exchange.

Kinichiro earned his Ph.D. degree (D. Sci.) from the Graduate School of Science, the University of Tokyo in 1994, and then worked at the Imperial Cancer Research Fund Laboratories (U.K.) as a postdoctoral fellow. He became an assistant at the Medical Institute of Bioregulation, Kyushu University (molecular biology) in 1998.

Mitsubishi Gas Chemical Company, Inc.

Shinsei Capital Partners, Ltd.

Mitsubishi UFJ Capital Co., Ltd.

Innovation Engine Inc.

Sadao Suzuki was appointed as Audit & Supervisory Board Member of Veritas In Silico in 2019. He has firsthand experience in asset management at a life insurance company and a wealth of experience as an audit & supervisory board member.

Prior to joining Veritas In Silico, Sadao joined Asahi Mutual Life Insurance Company in 1976, where he became Financial Review Manager in 2002, and then he served as Audit & Supervisory Board Member since 2008 at Asahi Mutual Life Insurance Company, TBK Co., Ltd., and Shin Corporation.

Sadao earned a bachelor’s degree in sociology from the Faculty of Letters, the University of Tokyo in 1976.

Minoru Hirooka, Head of Hirooka Certified Public Accountant Office, was appointed as Audit & Supervisory Board Member of Veritas In Silico in 2019. He is a certified public accountant and licensed tax accountant, not only providing services such as accounting audits, tax advising, business valuation, and listing support, but also enhancing governance systems as a non-executive officer of listed companies.

Minoru set up Hirooka Certified Public Accountant Office in 2009. He engaged in accounting audit, listing support, and other services at a major auditing firm from 1997 to 2008.

Minoru earned a bachelor’s degree in Business and Commerce from Keio University in 1995.

Minako Wakabayashi, a lawyer and partner in Orrick’s Tokyo office (Foreign Law Joint Enterprise), was appointed as Audit & Supervisory Board Member of Veritas In Silico in 2022. She is a member of Orrick’s Energy & Infrastructure Group and has been accelerating the growth of renewable energy markets in Japan. She currently serves as Auditor of the Japan Wind Power Association (JWPA) and has eight years of experience as a member of the Tokyo Metropolitan Government Supervising Committee for Public Bidding.

Minako joined Orrick in 2004. Prior to that, she served as a public prosecutor since 1998 at Tokyo, Saitama, and Mito District Public Prosecutor’s Offices, after completing the course at the Legal Training and Research Institute, the Supreme Court of Japan.

Minako earned a bachelor’s degree in Economics from Keio University in 1996, and a master’s degree in law (LLM) from the University of Chicago Law School in 2004.